Preoperative low hematocrit is an adverse prognostic biomarker in ovarian cancer
- PDF / 1,864,789 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 71 Downloads / 170 Views
GYNECOLOGIC ONCOLOGY
Preoperative low hematocrit is an adverse prognostic biomarker in ovarian cancer Junchen Chen1,2 · Yi Li1,2 · Heng Cui1,2 Received: 18 August 2019 / Accepted: 25 September 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Objective The study aimed to investigate the prognostic value of preoperative hematocrit (HCT) on the survival of epithelial ovarian cancer (EOC) patients. Methods Patients who underwent primary debulking surgery (PDS) in our institution, from January 2010 to December 2015, were enrolled. The preoperative HCT, hemoglobin (Hb), tumor stage, ascites volume, age, albumin, BMI, ASA score, diabetes and other factors were collected and analyzed to find the risk factors for poor prognosis of EOC patients using Cox regression. Survival analysis was conducted with Kaplan–Meier method and log-rank test. Results 192 patients met the inclusion criteria. HCT
Data Loading...
